JenniferEadsMD

Oncology • Philadelphia, PA

Endocrine Cancer, Gastrointestinal Cancer, Hematologic Oncology

Assistant Professor, Medicine, Case Western Reserve University School of Medicine

Join to view full profile

Dr. Eads is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Eads' full profile

Already have an account?

Office
3400 Civic Center Blvd
Fl 3
Philadelphia, PA 19104
Phone+1 215-615-5858

Fax+1 215-615-3349

Education & Training

Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 2005 - 2009
Tufts University School of MedicineClass of 2005

Certifications & Licensure

PA State Medical License 2018 - 2024
OH State Medical License 2005 - 2019
American Board of Internal Medicine Medical Oncology

Clinical Trials

Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors Start of enrollment: 2007 Aug 16
Completed
Phase 1
Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction Start of enrollment: 2013 Aug 23
Terminated
Phase 1
Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer Start of enrollment: 2018 Dec 01
Withdrawn
Phase 1, Phase 2
Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery Start of enrollment: 2019 May 03
SUSPENDED
PHASE2, PHASE3
Join now to see all

Publications & Presentations

PubMed

Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group.
Lakshmi Rajdev, Gentry G King, Christopher H Lieu, Stacey A Cohen, Shubham Pant
JCO Precision Oncology. 2025-03-01
4 citations
Prediction ofLu-DOTATATE Therapy Outcomes in Neuroendocrine Tumor Patients Using Semi-Automatic Tumor Delineation onGa-DOTATATE PET/CT.
Hwan Lee, Sarit T Kipnis, Remy Niman, Sophia R O'Brien, Jennifer R Eads
Cancers. 2023-12-31
1 citations
Response to Letter to Editor re: "Combined Quantification of 18F-FDG and 68Ga-DOTATATE PET/CT for Prognosis in High-Grade Gastroenteropancreatic Neuroendocrine Neoplas...
Hwan Lee, Ryusuke Nakamoto, Stephen E Moore, Austin R Pantel, Jennifer R Eads
Academic Radiology. 2022-09-01

Press Mentions

Leap Therapeutics Presents Positive DKN-01 Clinical Data in Biliary Tract Cancers at American Society of Clinical Oncology (ASCO) 2017 Annual MeetingMay 17th, 2017
Neuroendocrine Tumor Treatment Options Are GrowingMarch 25th, 2016